At the November 18, 2026 House hearing, VA described ten initial facilities involved in psychedelic-treatment implementation or training. These are not ten confirmed treatment centers. VA has not disclosed how many clinicians at those facilities would deliver treatment or how much of their time would be available.
We tested one narrower question using a treatment schedule published by VA’s National Center for PTSD: what staffing would be required to complete 1,000 courses a year? This is a reproducible scenario, not a VA rollout forecast.
What the studied MDMA schedule requires
The VA’s September 2026 review describes the Lykos MDMA-assisted therapy research protocol: twelve 90-minute psychotherapy sessions plus three drug sessions lasting six to eight hours. Two therapists are needed for each drug session. The review does not establish one fixed staffing ratio for the non-drug visits.
- Low contact-time case: 12 × 1.5 hours × 1 therapist + 3 × 6 hours × 2 therapists = 54 clinician-hours per completed course.
- High contact-time case: 12 × 1.5 hours × 2 therapists + 3 × 8 hours × 2 therapists = 84 clinician-hours.
- Illustrative midpoint: 69 clinician-hours, assuming 1.5 therapists on average for non-drug visits and seven-hour drug sessions.
These are hours of direct clinician-patient contact. They exclude training, screening, recordkeeping, supervised practice, logistics, cancellations and any patient observation outside the specified sessions. And they describe one research protocol, not a future FDA-approved standard for all psychedelic treatments.
The workload of 1,000 complete courses
For 1,000 completed courses, the schedule entails 54,000–84,000 clinician-contact hours.
Suppose one clinician works 46 weeks of 40 hours each year (1,840 hours), with 60% of those hours assigned to these patient sessions. That is 1,104 available clinician-contact hours per full-time equivalent (FTE). Dividing gives 48.9–76.1 FTE, or 49–77 when rounded upward. At the 69-hour midpoint, the requirement is 62.5 FTE.
The 46-week work year and 60% allocation are explicit assumptions, not VA staffing data. Changing them changes the result. This is a workload identity, not an estimate of how many VA clinicians are ready.
How much would an illustrative network deliver?
The following scenarios test sensitivity to unknown staffing and treatment-site allocation. None is a statement of VA’s planned numbers.
| Hypothetical case | Treating sites | Clinical FTE/site | Share of working hours in patient sessions | Clinician-hours/course | Maximum complete courses/year |
|---|---|---|---|---|---|
| Constrained | 4 | 2 | 50% | 84 | 87 |
| Middle | 7 | 4 | 60% | 69 | 448 |
| Optimistic | 9 | 8 | 70% | 54 | 1,717 |
All three are mathematical ceilings within the assumed budget of direct patient-contact hours. Real capacity could be lower because rooms, scheduling, safety supervision, training and referral availability can independently constrain throughput.
Reproduction formula: floor(treating sites × assigned clinical FTE per site × 1,840 × share of hours in patient sessions ÷ clinician-hours per completed course).
What would turn readiness into a measurable claim?
For each initial facility, VA would need to report whether it will treat patients or mainly train staff, the number of clinicians qualified for the actual treatment, their FTE assigned to delivery, the number of supervised dosing teams, treatment-room days, and the expected patient throughput under any approved protocol. Travel and referral options for veterans outside those locations are a separate access constraint.
The preliminary figure of about 180,000 potentially qualifying veterans reported after the hearing is not a verified waiting list. It does not establish eligibility for this particular MDMA protocol, whose future regulatory status and conditions remain unsettled.
The straightforward conclusion is that a count of facilities is not a count of treatment capacity. If VA publishes the site-level staffing plan requested at the hearing, these assumptions can be replaced with real numbers and the estimate tested.
Methods and sources
The arithmetic above is a deterministic sensitivity model. It uses no patient-level data and makes no inference about clinical efficacy. Complete treatment-course counts are rounded down; clinician staffing requirements are rounded up. All non-protocol inputs are hypothetical.
- VA National Center for PTSD, “Psychedelic-Assisted Therapy for PTSD”, updated September 2026 (course durations and dosing staff).
- House Veterans’ Affairs Subcommittee hearing repository, November 18, 2026.
- Behavioral Wire, hearing coverage, November 19, 2026 (missing site-level capacity and mixed facility roles).
- Navy Times, hearing report, November 19, 2026 (preliminary screening number and staffing-plan request).
Limitation: VA’s actual patient throughput cannot be identified from currently public staffing and site-level data. This is a hypothetical planning calculation for one published trial model, not a forecast of clinical implementation.